PTS Diagnostics Expands Leadership Team
Strategic hires emphasize operations, international sales, research and development
The company has tapped the following individuals to continue to drive its rapid global expansion:
• James Anderson, MD – Medical Director
• Keith Moskowitz, PhD, MPM – Vice President, Technology & Development
• John Hurrell, PhD – Senior Vice President, International Sales
• Mark Morgan – Chief Financial Officer and Human Resources Officer
“The addition of these highly-acclaimed, ground-breaking professionals represents a significant step as we expand our product lines and global reach,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “Our company continues to grow. Demand is strong for both our CardioChek analyzers and our A1CNow monitoring systems. These new leaders join a proven and experienced senior management team. Together with our expansive distribution network, PTS Diagnostics will continue to expand and serve more healthcare screening companies, physician offices, healthcare organizations, and labs.”
Dr. Anderson is a physician with over 35 years of experience in metabolic research and pharmaceutical medicine. He was formerly Senior Medical Director for Diabetes and Cardiometabolic Medicine at Eli Lilly and Company. Dr. Anderson’s fellowships include the American College of Endocrinology and the faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK). Dr. Anderson will provide clinical oversight as the company reaches new customers.
Dr. Moskowitz brings 30 years of diagnostic and medical device research and development experience to PTS Diagnostics. His resume boasts a dozen FDA and internationally cleared diagnostics, devices, and controls, as well as over 40 patent applications, publications, and published abstracts. Dr. Moskowitz received a bachelor’s degree in Biochemistry from Rutgers University and a PhD in Biochemistry from Temple University School of Medicine. He is recognized as a Master Project Manager by the American Academy of Project Management. Dr. Moskowitz will lead PTS Diagnostics’ medical device innovation advancements.
Similarly, Dr. Hurrell is a seasoned healthcare executive with extensive diagnostic accomplishments. He has served as senior Executive Vice President, International Business for Seegene Inc., a molecular diagnostics company located in South Korea. Prior to Seegene, he was President and General Manager of two Quest Diagnostics subsidiaries, and was responsible for growing the overall business of the subsidiaries. He also has held senior leadership positions with Boehringer Mannheim (now Roche Diagnostics), Genzyme, TriPath Imaging, and Inproteo. Dr. Hurrell has a PhD from Melbourne University, Australia, and was a Fulbright Fellow at Massachusetts General Hospital in the Harvard Medical School. He will oversee PTS Diagnostics’ international sales efforts.
Mr. Morgan has more than 25 years of global finance and administration experience in life science and medical devices. He brings expertise in providing strategic leadership and significant experience supporting R&D, Supply Chain, and IT with companies including Pfizer, Bayer and Mylan Pharmaceuticals. Mr. Morgan holds an undergraduate degree in Accounting from Indiana State University and an MBA from Illinois State University. He will oversee all Finance and Accounting functions, as well as Human Resources.
“PTS Diagnostics’ goal is to provide a broad portfolio of world-class point-of-care diagnostic solutions. These new individuals, alongside our existing management team, will ensure our future success,” said Huffstodt.
About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow point-of-care systems.
All trademarks used or mentioned in this release are protected by law.